BioSpace News Archive

Manufacturing is Expected to Contract in 2020; Revenue to Decrease 10.3%; Capital Expenditures to Decrease 19.1%; Capacity Utilization Currently at 75.9%

The American Academy of Orthopaedic Surgeons expanded a list of specific tests and procedures that orthopaedic surgeons and patients should question as part of the Choosing Wisely® campaign, an initiative of the ABIM Foundation.

California Life Sciences Institute on Friday named American High School 11th grader Shreya Ramachandran the winner of CLSI’s 2020 Bay Area BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field.

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that Dr. Moncef Slaoui has resigned from Moderna’s Board of Directors upon appointment of his new role to oversee the White House’s Operation Warp Speed initiative.

Aesculap Inc., in partnership with The Christoph Miethke GmbH & Co. KG (MIETHKE), is pleased to announce the launch of the M.blue valve, the latest generation of Hydrocephalus valve technology

Medtronic plc (NYSE:MDT) today announced results from two late-breaking clinical trials presented virtually at the 2020 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions.

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that the journal Frontiers of Immunology (“Frontiers”) released the results of the exploratory study on Treatment on a cohort of confirmed COVID-19 cases in Wuhan

Today, the U.S. Food and Drug Administration approved Qinlock (ripretinib) tablets as the first new drug specifically approved as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract.

Penumbra, Inc. (NYSE: PEN) today announced that the format for its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) has been changed from an in-person meeting to a virtual-only meeting at the previously announced date and time of June 3, 2020 at 11:00 a.m.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat during the 2020 RBC Capital Markets’ Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 10:20 a.m. E.D.T.